Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $63.00 at Truist Financial

Dianthus Therapeutics (NASDAQ:DNTH) had its target price raised by research analysts at Truist Financial from $56.00 to $63.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 63.88% from the company’s current price.

A number of other equities analysts have also recently issued reports on the stock. Wedbush restated an “outperform” rating and issued a $46.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. Stifel Nicolaus raised their target price on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright upped their target price on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.43.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock traded up $0.35 during trading hours on Thursday, reaching $38.44. The company had a trading volume of 160,674 shares, compared to its average volume of 569,610. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $45.46. The company has a 50-day moving average price of $40.54 and a 200 day moving average price of $31.80. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -11.08 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.58 million. As a group, research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Insider Activity at Dianthus Therapeutics

In other news, EVP Simrat Randhawa sold 109,031 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $38.14, for a total value of $4,158,442.34. Following the transaction, the executive vice president owned 4,000 shares in the company, valued at approximately $152,560. This represents a 96.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 216,538 shares of company stock worth $8,283,175. Insiders own 8.15% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP raised its position in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares during the period. Vestal Point Capital LP increased its stake in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares in the last quarter. Braidwell LP bought a new stake in Dianthus Therapeutics during the third quarter valued at about $32,859,000. Polar Capital Holdings Plc purchased a new position in shares of Dianthus Therapeutics in the third quarter valued at about $29,434,000. Finally, Fairmount Funds Management LLC lifted its position in shares of Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after acquiring an additional 600,000 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.